Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pemetrexed Dipotassium in Malignant Mesothelioma of Peritoneum: NCT03875144 Clinical Landscape Report 2026
16 October 2026
NCT03875144 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Nipocalimab-aahu in Myasthenia Gravis: NCT03896295 Clinical Landscape Report 2026
16 October 2026
NCT03896295 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Suvodirsen in Muscular Dystrophy, Duchenne: NCT03907072 Clinical Landscape Report 2026
16 October 2026
NCT03907072 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vitamin E Nicotinicate in Endothelial dysfunction: NCT03903133 Clinical Landscape Report 2026
16 October 2026
NCT03903133 clinical landscape for Endothelial dysfunction: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Capsaicin in Neuralgia: NCT03899246 Clinical Landscape Report 2026
16 October 2026
NCT03899246 clinical landscape for Neuralgia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Malignant Mesothelioma of Peritoneum: NCT03907852 Clinical Landscape Report 2026
16 October 2026
NCT03907852 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Salbutamol sulfate in Myasthenia Gravis: NCT03914638 Clinical Landscape Report 2026
16 October 2026
NCT03914638 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
APG-2449 in Malignant Pleural Mesothelioma: NCT03917043 Clinical Landscape Report 2026
16 October 2026
NCT03917043 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Malignant Pleural Mesothelioma: NCT03918252 Clinical Landscape Report 2026
16 October 2026
NCT03918252 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Human Coagulation Factor VIII (Takeda) in Hemophilia A: NCT03915080 Clinical Landscape Report 2026
16 October 2026
NCT03915080 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Edasalonexent in Muscular Dystrophy, Duchenne: NCT03917719 Clinical Landscape Report 2026
16 October 2026
NCT03917719 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ravulizumab-CWVZ in Myasthenia Gravis: NCT03920293 Clinical Landscape Report 2026
16 October 2026
NCT03920293 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.